These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 30142539)

  • 1. Interactions of casticin, ipriflavone, and resveratrol with serum albumin and their inhibitory effects on CYP2C9 and CYP3A4 enzymes.
    Mohos V; Bencsik T; Boda G; Fliszár-Nyúl E; Lemli B; Kunsági-Máté S; Poór M
    Biomed Pharmacother; 2018 Nov; 107():777-784. PubMed ID: 30142539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic interaction of diosmetin and silibinin with other drugs: Inhibition of CYP2C9-mediated biotransformation and displacement from serum albumin.
    Poór M; Boda G; Mohos V; Kuzma M; Bálint M; Hetényi C; Bencsik T
    Biomed Pharmacother; 2018 Jun; 102():912-921. PubMed ID: 29710546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of quercetin and its metabolites with warfarin: Displacement of warfarin from serum albumin and inhibition of CYP2C9 enzyme.
    Poór M; Boda G; Needs PW; Kroon PA; Lemli B; Bencsik T
    Biomed Pharmacother; 2017 Apr; 88():574-581. PubMed ID: 28135601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions of 7,8-Dihydroxyflavone with Serum Albumin as well as with CYP2C9, CYP2C19, CYP3A4, and Xanthine Oxidase Biotransformation Enzymes.
    Fliszár-Nyúl E; Mohos V; Bencsik T; Lemli B; Kunsági-Máté S; Poór M
    Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31731555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of the Hepatocyte-to-Plasma pH Gradient on the Prediction of Hepatic Clearance and Drug-Drug Interactions for CYP2C9 and CYP3A4 Substrates.
    Rougée LRA; Mohutsky MA; Bedwell DW; Ruterbories KJ; Hall SD
    Drug Metab Dispos; 2017 Sep; 45(9):1008-1018. PubMed ID: 28679672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of CYP3A4 and CYP2C9 activity by Bulbine natalensis and its constituents: An assessment of HDI risk of B. natalensis containing supplements.
    Husain I; Manda V; Alhusban M; Dale OR; Bae JY; Avula B; Gurley BJ; Chittiboyina AG; Khan IA; Khan SI
    Phytomedicine; 2021 Jan; 81():153416. PubMed ID: 33321412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of resveratrol and its metabolites (resveratrol-3-sulfate, resveratrol-3-glucuronide, and dihydroresveratrol) with serum albumin, cytochrome P450 enzymes, and OATP transporters.
    Poór M; Kaci H; Bodnárová S; Mohos V; Fliszár-Nyúl E; Kunsági-Máté S; Özvegy-Laczka C; Lemli B
    Biomed Pharmacother; 2022 Jul; 151():113136. PubMed ID: 35594715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of 95% Ethanol Khat Extract and Cathinone on in vitro Human Recombinant Cytochrome P450 (CYP) 2C9, CYP2D6, and CYP3A4 Activity.
    Lim SYM; Binti Azidin AR; Ung YT; Al-Shagga M; Alshawsh MA; Mohamed Z; Ong CE; Pan Y
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):423-431. PubMed ID: 30306496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of luteolin, naringenin, and their sulfate and glucuronide conjugates with human serum albumin, cytochrome P450 (CYP2C9, CYP2C19, and CYP3A4) enzymes and organic anion transporting polypeptide (OATP1B1 and OATP2B1) transporters.
    Kaci H; Bodnárová S; Fliszár-Nyúl E; Lemli B; Pelantová H; Valentová K; Bakos É; Özvegy-Laczka C; Poór M
    Biomed Pharmacother; 2023 Jan; 157():114078. PubMed ID: 36481402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of myricetin, ampelopsin (dihydromyricetin), and their sulfate metabolites with serum albumin, cytochrome P450 (CYP2C9, 2C19, and 3A4) enzymes, and organic anion-transporting polypeptides (OATP1B1 and OATP2B1).
    Dombi Á; Kaci H; Valentová K; Bakos É; Özvegy-Laczka C; Poór M
    Pharmacol Res Perspect; 2024 Oct; 12(5):e70021. PubMed ID: 39344282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity.
    Kimura Y; Ito H; Ohnishi R; Hatano T
    Food Chem Toxicol; 2010 Jan; 48(1):429-35. PubMed ID: 19883715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction.
    Fang ZZ; Zhang YY; Ge GB; Huo H; Liang SC; Yang L
    Br J Clin Pharmacol; 2010 Feb; 69(2):193-9. PubMed ID: 20233183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pogostone inhibits the activity of CYP3A4, 2C9, and 2E1
    Zhang G; Zhang Y; Ma X; Yang X; Cai Y; Yin W
    Pharm Biol; 2021 Dec; 59(1):532-536. PubMed ID: 33915070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent inhibitory effect of alpha-viniferin on human cytochrome P450.
    Sim J; Jang HW; Song M; Kim JH; Lee SH; Lee S
    Food Chem Toxicol; 2014 Jul; 69():276-80. PubMed ID: 24769006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
    Eng H; Obach RS
    Drug Metab Dispos; 2016 Aug; 44(8):1217-28. PubMed ID: 27271369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Prediction of Cytochrome P450-Drug Interaction: QSARs for CYP3A4 and CYP2C9.
    Nembri S; Grisoni F; Consonni V; Todeschini R
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27294921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening of Drug Metabolizing Enzymes for the Ginsenoside Compound K In Vitro: An Efficient Anti-Cancer Substance Originating from Panax Ginseng.
    Xiao J; Chen D; Lin XX; Peng SF; Xiao MF; Huang WH; Wang YC; Peng JB; Zhang W; Ouyang DS; Chen Y
    PLoS One; 2016; 11(2):e0147183. PubMed ID: 26845774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Study 9: Probe-Dependent Binding Explains Lack of CYP2C9 Inactivation by 1-Aminobenzotriazole (ABT).
    Sodhi JK; Halladay JS
    Methods Mol Biol; 2021; 2342():765-779. PubMed ID: 34272716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans.
    Thörn HA; Lundahl A; Schrickx JA; Dickinson PA; Lennernäs H
    Eur J Pharm Sci; 2011 Jun; 43(3):89-98. PubMed ID: 21447389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.